Sotagliflozin benefits held across blood pressure levels
In a randomized trial of 1,222 patients, benefits did not differ across starting systolic blood pressures of about 90 to 180 mmHg.
Placebo-controlled
Limit: Treatment dose, follow-up duration, and numerical adverse-event rates were not reported
Edited by Boris Djordjevic · AgingResearch.News
The SOLOIST-WHF randomized trial enrolled 1,222 people with type 2 diabetes hospitalized for worsening heart failure. Patients started sotagliflozin or a matching placebo in the hospital or within three days after discharge. This analysis examined whether benefits varied with systolic blood pressure, the upper number in a blood pressure reading.
The reduction in cardiovascular deaths and hospitalizations or urgent visits for heart failure did not differ across starting blood pressure levels. Among 201 patients below 110 mmHg, sotagliflozin reduced these events compared with placebo. The hazard ratio, a measure of relative risk, was 0.56. In patients with low blood pressure, starting sotagliflozin was not associated with more episodes of low blood pressure or acute kidney injury, a sudden decline in kidney function.
Why it matters
For heart failure, an age-related disease, the analysis informs decisions about starting medication when low blood pressure raises concerns about kidney injury or further pressure drops.
Caveats
This blood-pressure subgroup analysis appeared in a conference abstract without treatment dose, follow-up duration or numerical adverse-event rates. All participants had type 2 diabetes and qualified with systolic pressure of at least 100 mmHg at screening, so the findings do not cover all patients with low blood pressure.
The paper
Benefits of sotagliflozin across the full range of baseline blood pressure in the SOLOIST-WHF Trial
Icahn School of Medicine at Mount Sinai; University of Michigan
ESC Congress 2026 Abstract, Oct 26, 2026
Presented at ESC Congress 2026
